CSPC PHARMA (01093): CSPC Innovation Pharmaceutical's net profit attributable to shareholders for the first three quarters was RMB1.21 billion.
CSPC PHARMA (01093) announced that its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (CSPC Innovation) recorded operating revenue of RMB3.976 billion for the first three quarters of 2026, an increase of 149.62% year-on-year; net profit attributable to shareholders of the listed company was RMB1.21 billion; basic earnings per share were RMB0.8688.
CSPC PHARMA (01093) announced that its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (CSPC Innovation Pharmaceutical) recorded operating revenue of RMB3.976 billion for the first three quarters of 2026, an increase of 149.62% year-on-year; net profit attributable to shareholders of the listed company was RMB1.21 billion; basic earnings per share were RMB0.8688.
Related Articles
WEIYE HOLDINGS (01570) changes its name to "Dingjisheng International Holdings Limited"
ASIAINFO TECH(01675) Reports Revenue of Approximately RMB3.38 billion for the First Three Quarters, with Order Contract Value in the Non-Operator Market Achieving Doubled Growth
EDDING GENOR (06998) repurchased 500,000 shares for HK$785,000 on October 28.
WEIYE HOLDINGS (01570) changes its name to "Dingjisheng International Holdings Limited"
ASIAINFO TECH(01675) Reports Revenue of Approximately RMB3.38 billion for the First Three Quarters, with Order Contract Value in the Non-Operator Market Achieving Doubled Growth
EDDING GENOR (06998) repurchased 500,000 shares for HK$785,000 on October 28.
